Table 5.
Study | Study Design | Trigger Fingers Analyzed (N) | Definition of Failure | Second Injection Success | Third Injection Success | Duration of Follow-Up¥ |
---|---|---|---|---|---|---|
Clark et al.4 | Retrospective | 76 | Return of symptoms | 33% | 50% | 44 months |
Newport et al.2 | Retrospective | 356 | No improvement in symptoms | 23% | 5%§ | 35 months (11–105 months) |
Anderson et al.5 | Prospective | 77 | Return of symptoms | 59% | ---- | 4.6 years |
Benson et al.17 | Retrospective | 109 | Return of symptoms | 36% | 33% | 18 months |
Rozental et al.13 | Prospective | 124 | Surgical release | 79% | ---- | 12.6 months (12.1–13.2 months) |
Dala-Ali et al.9 | Retrospective | 90 | Injection or surgery | 44% | 6% | 1 year minimum |
Schubert et al.10 | Retrospective | 577 | Injection or surgery | 52% | 74% | 66.4 months (2–152 months) |
Castellanos et al.11 | Prospective | 71 | Return of symptoms | 68% | 8 years (7–8 years) |
Median (range)
5% for 3–5 injections